2-imidazolines Patents (Class 514/401)
  • Patent number: 10562859
    Abstract: Disclosed herein are compounds having the following structure useful as inhibitors of carbonic anhydrase IX (CAIX) and XII, and particularly useful for reducing or eliminating metastases see Formula (I).
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: February 18, 2020
    Assignee: SIGNALCHEM LIFESCIENCES CORPORATION
    Inventor: Zaihui Zhang
  • Patent number: 10335391
    Abstract: The present invention provides stabilized cream formulations of oxymetazoline and uses thereof. The present invention also provides a method of treating facial erythema associated with rosacea in a patient in need of such treatment, comprising topically administering once or twice daily to the site of erythema on the face of the patient a pharmaceutical composition comprising 0.5%, 1.0% or 1.5% oxymetazoline or a pharmaceutically acceptable salt thereof as the sole active ingredient.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: July 2, 2019
    Assignee: ACLARIS THERAPEUTICS, INC.
    Inventors: Pramod Sarpotdar, Kevin Warner, Steven Zhang, Gurpreet Ahluwalia, Amy Kuang
  • Patent number: 10092609
    Abstract: The invention provides medicinal fungal preparations that have twenty or more times more medicinal potency than corresponding medicinal fungal preparations made by prevailing means in the prior art. In particular the invention provides nutrient-supplemented bioactive cell-ruptured cultures of medicinal fungi for which the post-rupture extraction medium is edible or potable, and has no significant side effects. The invention further provides methods to prepare them, and pharmacological preparations based on whole-culture biomass including the growth medium and metabolites.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: October 9, 2018
    Inventors: James A. Wieser, James Martin Bell, Richard L. Sarnat
  • Patent number: 9981070
    Abstract: A coating composition capable of forming a drug coating layer insusceptible to peeling in the process of delivery of a water-insoluble drug to a target tissue is provided. The coating composition contains the water-insoluble drug and a basic compound which is positively charged at physiological pH. A medical device coated with the coating composition is further provided.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: May 29, 2018
    Assignee: TERUMO KABUSHIKI KAISHA
    Inventors: Keiko Yamashita, Shigenori Nozawa
  • Patent number: 9974773
    Abstract: The present invention provides stabilized cream formulations of oxymetazoline and uses thereof. The present invention also provides a method of treating facial erythema associated with rosacea in a patient in need of such treatment, comprising topically administering once or twice daily to the site of erythema on the face of the patient a pharmaceutical composition comprising 0.5%, 1.0% or 1.5% oxymetazoline or a pharmaceutically acceptable salt thereof as the sole active ingredient.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: May 22, 2018
    Assignee: Allergan, Inc.
    Inventors: Pramod Sarpotdar, Kevin Warner, Steven Zhang, Gurpreet Ahluwalia, Amy Kuang
  • Patent number: 9968572
    Abstract: Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine and a gamma-aminobutyric acid compound at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.
    Type: Grant
    Filed: March 31, 2016
    Date of Patent: May 15, 2018
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: Jared T. Wilsey, Danielle L. Clay, Jeffrey C. Marx, William F. McKay, Josee Roy, John Myers Zanella
  • Patent number: 9827225
    Abstract: The present invention relates generally to the use of compositions and methods for treating nociceptive events that occur on the ocular surface in association with dryness, injury, environmental pollutants, and infectious and non-infectious diseases. Specifically, the present invention is directed to the use of certain compounds for treating for treating ocular pain or ocular discomfort.
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: November 28, 2017
    Assignee: JENIVISION INC.
    Inventors: David Frederick Woodward, Weizhen Wang
  • Patent number: 9801941
    Abstract: An oral, aqueous-based, liquid pharmaceutical composition is provided. The composition comprises up to about 45% glycerin and up to about 10% sorbitol wherein the glycerin to sorbitol ratio is about 2:1 to 10:1.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: October 31, 2017
    Assignee: Wyeth LLC
    Inventors: Amanda Alley, William Bubnis, Stephanie Shield
  • Patent number: 9750723
    Abstract: Methods for preventing, treating, and/or reducing the risk of developing non-alcoholic fatty liver disease in a subject in need thereof and pharmaceutical compositions for the prevention or treatment of non-alcoholic fatty liver disease. The methods include administering a therapeutically effective amount of phenylmethimazole, methimazole derivatives, and/or tautomeric cyclic thiones to the subject. The pharmaceutical composition includes phenylmethimazole, methimazole derivatives, and/or tautomeric cyclic thiones formulated for administration to a subject for the prevention or treatment of non-alcoholic fatty liver disease.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: September 5, 2017
    Assignee: Ohio University
    Inventors: Kelly D. McCall, Frank L. Schwartz, Douglas J. Goetz, Ramiro Malgor
  • Patent number: 9753018
    Abstract: The invention provides a method of improving an antioxidant effect in a redox pathway that involves selenium in a subject, an in vitro method of inhibiting oxidation in a cell or tissue, and an in vitro method of promoting proliferation of a cell, by use of a selenium-containing compound of chemical formula 1:
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: September 5, 2017
    Assignee: Fisheries Research Agency
    Inventors: Yumiko Yamashita, Michiaki Yamashita, Takeshi Yabu
  • Patent number: 9629789
    Abstract: Described herein are novel methods for the treatment of rosacea which include the step of applying of a composition containing a polymetal complex to an area of the skin afflicted with rosacea and novel regimens using such compounds.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: April 25, 2017
    Assignee: Obagi Medical Products, Inc.
    Inventors: Joseph R. Faryniarz, Jose E Ramirez, Hovig Ounian
  • Patent number: 9393231
    Abstract: The invention provides a method of improving an antioxidant effect in a redox pathway that involves selenium in a subject, an in vitro method of inhibiting oxidation in a cell or tissue, and an in vitro method of promoting proliferation of a cell, by use of a selenium-containing compound of chemical formula 1:
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: July 19, 2016
    Assignee: Fisheries Research Agency
    Inventors: Yumiko Yamashita, Michiaki Yamashita, Takeshi Yabu
  • Patent number: 9303061
    Abstract: Disclosed are spiro compounds of formula (I), or stereomers, geometric isomers, tautomers, nitrogen oxides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof. The compounds can be used to treat hepatitis C virus (HCV) infection or hepatitis C disease. Furthermore disclosed are pharmaceutical compositions containing the compounds and the method of using the compounds or pharmaceutical compositions in the treatment of HCV infection or hepatitis C disease.
    Type: Grant
    Filed: July 9, 2012
    Date of Patent: April 5, 2016
    Assignee: Sunshine Luke Pharma Co., Ltd.
    Inventors: Jiancun Zhang, Yingjun Zhang, Hongming Xie, Qingyun Ren, Huichao Luo, Tianzhu Yu, Yumei Tan
  • Patent number: 9233099
    Abstract: Methods for treating cognitive dysfunction by modulating brain energy metabolizm using cyclocreatine or a pharmaceutically acceptable salt thereof are discussed.
    Type: Grant
    Filed: April 30, 2014
    Date of Patent: January 12, 2016
    Assignees: University of Cincinnati, Children's Hospital Medical Center
    Inventors: Joseph F. Clark, Antonius J. de Grauw
  • Patent number: 9211284
    Abstract: A method for treating a patient having P.R.I.C.E. Syndrome is disclosed. The method includes administering to the patient a therapeutically effective amount of an alpha-2 adrenergic agonist in an extended release dosage form.
    Type: Grant
    Filed: April 11, 2013
    Date of Patent: December 15, 2015
    Inventor: Richard Louis Price
  • Patent number: 9109158
    Abstract: A novel selenium-containing compound, a method of producing the selenium-containing compound, an analysis method using the selenium-containing compound, and use of the selenium-containing compound as an antioxidant, are disclosed. A novel selenium-containing compound shown by any of chemical formulas 1 to 4 is obtained by extracting a selenium-containing compound from a sample using an organic solvent or water, and purifying the selenium-containing compound. The novel selenium-containing compound may be used for a novel analysis method, or may be used as an antioxidant.
    Type: Grant
    Filed: November 17, 2010
    Date of Patent: August 18, 2015
    Assignee: Fisheries Research Agency
    Inventors: Yumiko Yamashita, Michiaki Yamashita, Takeshi Yabu
  • Publication number: 20150148397
    Abstract: Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.
    Type: Application
    Filed: January 29, 2015
    Publication date: May 28, 2015
    Inventors: John M. Zanella, Christopher M. Hobot, Danielle L. Biggs, Katara Shaw, Phillip Edward McDonald, Vanja Margareta King, William F. McKay, Kathy L. Remsen
  • Publication number: 20150148398
    Abstract: The present invention concerns a pharmaceutical composition comprising an alpha-2 adrenergic receptor agonist for preventing or treating inflammatory pain and diseases in mucosa of oral cavity, pharynx and larynx. In another aspect the present invention provides mucosal bioadhesive slow release carriers for the extended and controlled release of alpha-2 adrenergic receptor agonists that can be used on mucosal surfaces for preventing or treating inflammatory pain and diseases in mucosa of oral cavity.
    Type: Application
    Filed: February 2, 2015
    Publication date: May 28, 2015
    Inventors: Pierre ATTALI, Caroline LEMARCHAND, Vanessa ROULET, Claire SCHEUIR, Lorraine ZAKIN
  • Publication number: 20150148396
    Abstract: Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.
    Type: Application
    Filed: January 29, 2015
    Publication date: May 28, 2015
    Inventors: John Myers Zanella, Christopher M. Hobot, Danielle L. Biggs, Katara Shaw, Phillip Edward McDonald, Vanja Margareta King, William F. McKay, Kathy L. Remsen
  • Publication number: 20150140137
    Abstract: Compositions and methods for alleviating an allergy condition while also reducing a drying effect of an allergy treatment composition or another anti-mucosal composition. In some embodiments and implementations, a composition may be provided comprising an allergy treatment composition comprising an antihistamine in a therapeutically effective amount for treating the allergy condition in the human having the allergy condition. The composition may further comprise an anti-drying composition comprising at least one of xylitol, erythiritol, mannitol, maltitol, tibitol, arabitol, ribose, and xylose in one or more therapeutically effective amounts for reducing nasal dryness caused by the allergy treatment composition. The composition may be delivered into at least one of the human's nose, eyes, mouth, and throat.
    Type: Application
    Filed: January 27, 2015
    Publication date: May 21, 2015
    Inventors: Alonzo H. Jones, Nathan Jones
  • Publication number: 20150139973
    Abstract: The present invention relates to an ophthalmological vehicle system for the permeation and/or for the active substance transport of ophthalmological active substances through the cornea and/or the sclera of the eye of mammals. This vehicle system assists the transport of the active substances through the cornea and/or the sclerotic tissue of the eye. The vehicle system is suitable for the prophylaxis and/or treatment of diseases of the front and/or back portion of the eye. Likewise, the present invention relates to an ophthalmological kit, comprising a special ophthalmological composition and also, as separate formulation, an ophthalmological active substance.
    Type: Application
    Filed: May 14, 2013
    Publication date: May 21, 2015
    Inventors: Ute Steinfeld, Frank Holzer, Hyeck Hee Lee, Markus Mahler
  • Patent number: 9034910
    Abstract: Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an ?-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, acute, neuropathic and chronic.
    Type: Grant
    Filed: October 17, 2011
    Date of Patent: May 19, 2015
    Assignee: Allergan, Inc.
    Inventors: Daniel W. Gil, John E. Donello, Wenkui K. Fang, Phong X. Nguyen, Ken Chow, Todd M. Heidelbaugh, Dario G. Gomez, Michael E. Garst, Santosh C. Sinha
  • Publication number: 20150126572
    Abstract: A method for treating a patient having ASD is disclosed. The method includes administering to the patient a plurality of comestible units, e.g., cookies, cumulatively comprising a therapeutically effective amount of inositol. The method may further include administering to the patient a therapeutically effective amount of an alpha-2 adrenergic agonist in an extended release dosage form.
    Type: Application
    Filed: January 14, 2015
    Publication date: May 7, 2015
    Inventor: Richard Louis Price
  • Publication number: 20150125559
    Abstract: A method of constructing a data architecture for use in identifying connections between perturbagens and genes associated with a type of periorbital dyschromia. The method includes providing a gene expression profile for a keratinocyte, fibroblast, melanocyte or melanoma cell, which has been exposed to at least one perturbagen, and comparing the gene expression profile to a control cell from the same cell line. Genes that are differentially expressed in response to the perturbagen are identified by comparing the gene expression profiles of the control cell and the test cell. An ordered list of identifiers representing the differentially expressed genes is created according to the differential expression of the genes. The ordered list is stored as an instance on a computer readable medium. The steps are then repeated to construct a data architecture of stored instances.
    Type: Application
    Filed: August 29, 2014
    Publication date: May 7, 2015
    Inventors: Karen Marie OSORIO, Wenzhu ZHAO
  • Publication number: 20150119437
    Abstract: Methods for treating cognitive dysfunction by modulating brain energy metabolism using cyclocreatine or a pharmaceutically acceptable salt thereof are discussed.
    Type: Application
    Filed: January 9, 2015
    Publication date: April 30, 2015
    Inventors: Joseph F. Clark, Antonius J. de Grauw
  • Patent number: 9012486
    Abstract: Described is a topically applied composition relief of pain. Also described are methods of preparing the composition and methods of using the composition to relieve pain.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: April 21, 2015
    Inventor: Alex Chervinsky
  • Patent number: 8999368
    Abstract: The implant design is a drug loaded polymer device, such as a rod, designed to control the release of a biologically active agent, such as clonidine or its derivatives, such as clonidine HCl for a prolonged period of time, such as 2 months, 3 months, 4 months, and even 4.5 months. The polymer is preferably a biodegradable polymer, such as poly(lactide-co-glycolide) or polylactic acid/polylactide. The challenge in using the HCl salt forms of drugs such as clonidine, is controlling the release of the highly water soluble drug for up to 4.5 months. It has been found that by controlling the particle size distribution of the drug powder, the drug distribution within the polymer matrix is more uniform and can be controlled. Therefore, the large aggregates, which cause rapid drug release can be eliminated.
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: April 7, 2015
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: Phillip E. McDonald, Kathy L. Remsen
  • Patent number: 8993571
    Abstract: In methods, compounds, and topical formulations for treatment of inflammatory skin disorders incorporating compounds represented by the formulas below: wherein each of R1, R2, and R3 is independently hydrogen, hologen, alkyl, or alkoxy; each of R4 and R5 is independently hydrogen, alkyl, or alkoxy; and each of R6 and R7 is independently hydrogen, nitro, alkyl, or alkoxy; wherein each of A1, A3, and A4 is independently hydrogen or alkyl; and A2 is independently hydrogen or hydroxy; and wherein each of B1, B2, and B3 is independently hydrogen, hydroxy, or alkoxy; and each of B4 and B5 is independently hydrogen or alkyl, applying such compounds topically as sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions, and suspensions to treat inflammatory skin disorders and the symptoms associated therewith.
    Type: Grant
    Filed: February 25, 2013
    Date of Patent: March 31, 2015
    Assignee: Galderma Laboratories, L.P.
    Inventors: Jack A. DeJovin, Isabelle Jean DeJovin
  • Patent number: 8980952
    Abstract: The present invention is directed to therapeutic compounds, treatment methods, and kits affecting the NCCa-ATP channel of neural tissue, including neurons, glia and blood vessels within the nervous system, and methods of using same. The NCCa-ATP channel is newly expressed in neural tissue following injury such as ischemia, and is regulated by the sulfonylurea receptor SUR1, being inhibited by sulfonylurea compounds, e.g., glibenclamide and tolbutamide, and opened by diazoxide. Antagonists of the NCCa-ATP channel, including SUR1 antagonists, are useful in the prevention, diminution, and treatment of injured or diseased neural tissue, including astrocytes, neurons and capillary endothelial cells, that is due to ischemia, tissue trauma, brain swelling and increased tissue pressure, or other forms of brain or spinal cord disease or injury. Agonists of the NCCa-ATP channel may be are useful in the treatment neural tissue where damage or destruction of the tissue, such as a gliotic capsule, is desired.
    Type: Grant
    Filed: February 22, 2006
    Date of Patent: March 17, 2015
    Assignees: University of Maryland, Baltimore, The United States of America as represented by the Dept. of Veterans Affairs
    Inventors: J. Marc Simard, Mingkui Chen
  • Publication number: 20150057325
    Abstract: The present invention relates to novel uses of compounds that protect the endothelium, particularly prostacyclin and variants and derivatives thereof in the treatment or prevention of acute traumatic coagulopathy (ATC) and of patients resuscitating from cardiac arrest. The invention also relates to a method of identifying individuals at risk of developing ATC.
    Type: Application
    Filed: March 26, 2013
    Publication date: February 26, 2015
    Applicant: Rigshospitalet
    Inventors: Pär Johansson, Sisse Rye Ostrowski
  • Publication number: 20150044148
    Abstract: The invention relates to a method of treating capillary hemangiomas in a human in need thereof by topically administering an effective amount of one or more alpha-2 adrenergic receptors agonist to the site of the capillary hemangiomas on the skin of the human.
    Type: Application
    Filed: October 15, 2012
    Publication date: February 12, 2015
    Inventor: Warren J. Scherer
  • Patent number: 8946277
    Abstract: Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.
    Type: Grant
    Filed: April 8, 2009
    Date of Patent: February 3, 2015
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: John Myers Zanella, Christopher M. Hobot, Danielle L. Biggs, Katara Shaw, Phillip Edward McDonald, Vanja Margareta King, William F. McKay, Kathy L. Remsen
  • Publication number: 20150005356
    Abstract: This invention relates to pharmaceutical compositions of epinephrine for delivery to the nasal mucosa and methods of treating a subject in acute severe anaphylaxis, bronchospasm or during cardiopulmonary resuscitation (CPR). The composition further comprising agents, that either prevent localized degradation of epinephrine or enhance its absorption in the nasal mucosa to counter anaphylactic effects, symptoms or complications in a subject.
    Type: Application
    Filed: June 27, 2013
    Publication date: January 1, 2015
    Applicant: G2B PHARMA INC.
    Inventor: Nigel Ten Fleming
  • Publication number: 20140364475
    Abstract: The invention features topical formulations comprising an osmotically active agent and/or a vasoconsgtrictor and/or an astringent agent for the treatment and prevention of eyelid swelling, and methods of use thereof.
    Type: Application
    Filed: April 10, 2014
    Publication date: December 11, 2014
    Applicant: ACIEX THERAPEUTICS, INC.
    Inventors: Matthew Jonathan CHAPIN, Mark Barry ABELSON, Keith Jeffrey LANE, George MINNO
  • Publication number: 20140350041
    Abstract: Methods for treating a disease condition in a subject are provided. The subject methods are characterizing by enhancing at least one symptom of the disease condition in a manner effective to cause the subject to mount a compensatory response effective to treat the disease condition. Also provided are compositions, kits and systems for practicing the subject methods.
    Type: Application
    Filed: June 10, 2014
    Publication date: November 27, 2014
    Inventors: Anthony Joonkyoo Yun, Patrick Yuarn-Bor Lee
  • Publication number: 20140343067
    Abstract: The present invention relates to a method of reducing cutaneous facial flushing caused by systemic use of phosphodiesterase type 5 (PDE5) inhibitors by topical facial dermatological application of an effective dose of a composition comprising at least one alpha adrenergic receptor agonist.
    Type: Application
    Filed: October 12, 2012
    Publication date: November 20, 2014
    Inventors: Warren J. Scherer, Arthur Clapp, Philippe Andres
  • Patent number: 8883838
    Abstract: The present invention provides pharmaceutical cream compositions comprising oxymetazoline and methods for treating rosacea and other skin disorders as described herein using the above cream compositions.
    Type: Grant
    Filed: December 1, 2011
    Date of Patent: November 11, 2014
    Assignee: Allergan, Inc.
    Inventors: Stuart D. Shanler, Christopher Powala, Luis Rios
  • Publication number: 20140329874
    Abstract: The present invention provides a method of treating tissue trauma (such as damage from radiation (such as solar and ultraviolet radiation), wounds, bruising, burns, blisters, excoriations, incisions, excisions, and ulcers) in a subject, comprising topically administering to the tissue area of the subject affected by said trauma a composition comprising a therapeutically effective amount of at least one alpha adrenergic agonist (such as oxymetazoline hydrochloride). The present invention also provides a method for alleviating the pain or discomfort associated with aesthetic or plastic surgery or cosmetology procedures in a subject comprising administering said alpha adrenergic agonist.
    Type: Application
    Filed: May 5, 2014
    Publication date: November 6, 2014
    Applicant: Allergan, Inc.
    Inventors: Daniel W. Gil, Lydia L. Andrews-Jones, Edward C. Hsia, Mingting Tian
  • Patent number: 8877793
    Abstract: The present invention is directed to the treatment of skin erythema as exhibited in rosacea and other conditions characterized by increased erythema (redness) of the skin. These conditions exhibit dilation of blood vessels due to a cutaneous vascular hyper-reactivity. In particular, the present invention is directed to a novel composition and method for the treatment of skin erythema using ?1-adrenergic receptor (?1-adrenoceptor) agonists incorporated into cosmetic, pharmacological or dermatological compositions for topical application to the skin.
    Type: Grant
    Filed: October 11, 2010
    Date of Patent: November 4, 2014
    Assignee: Allergan, Inc.
    Inventors: Stuart D. Shanler, Andrew Ondo
  • Publication number: 20140323483
    Abstract: The invention, in some aspects, relates to compounds and compositions useful for inhibiting Type III secretion systems in pathogenic bacteria, such as Yersinia Pestis. In some aspects, the invention relates to methods for discovering inhibitors of the Type III secretion system and uses of such inhibitors in the treatment and prevention of disease.
    Type: Application
    Filed: May 5, 2014
    Publication date: October 30, 2014
    Applicants: University of Massachusetts, President and Fellows of Harvard College
    Inventors: Jon Goguen, Ning Pan, Kyungae Lee
  • Publication number: 20140309271
    Abstract: A method for treating a patient having ASD is disclosed. The method includes administering to the patient a therapeutically effective amount of an alpha-2 adrenergic agonist in an extended release dosage form in combination with a therapeutically effective amount of inositol.
    Type: Application
    Filed: April 4, 2014
    Publication date: October 16, 2014
    Inventor: Richard Louis Price
  • Publication number: 20140309269
    Abstract: A method for treating a patient having P.R.I.C.E. Syndrome is disclosed. The method includes administering to the patient a therapeutically effective amount of an alpha-2 adrenergic agonist in an extended release dosage form.
    Type: Application
    Filed: April 11, 2013
    Publication date: October 16, 2014
    Inventor: Richard Louis Price
  • Publication number: 20140309270
    Abstract: A method for treating a patient having P.R.I.C.E. Syndrome is disclosed. The method includes administering to the patient a therapeutically effective amount of an alpha-2 adrenergic agonist in an extended release dosage form, optionally in combination with a therapeutically effective amount of inositol and/or NAC.
    Type: Application
    Filed: January 28, 2014
    Publication date: October 16, 2014
    Inventor: Richard Louis Price
  • Patent number: 8859551
    Abstract: In methods, compounds, and topical formulations for treatment of inflammatory skin disorders incorporating compounds represented by the formulas below: wherein each of R1, R2, and R3 is independently hydrogen, hologen, alkyl, or alkoxy; each of R4 and R5 is independently hydrogen, alkyl, or alkoxy; and each of R6 and R7 is independently hydrogen, nitro, alkyl, or alkoxy; wherein each of A1, A3, and A4 is independently hydrogen or alkyl; and A2 is independently hydrogen or hydroxy; and wherein each of B1, B2, and B3 is independently hydrogen, hydroxy, or alkoxy; and each of B4 and B5 is independently hydrogen or alkyl, applying such compounds topically as sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions, and suspensions to treat inflammatory skin disorders and the symptoms associated therewith.
    Type: Grant
    Filed: February 25, 2013
    Date of Patent: October 14, 2014
    Assignee: Galderma Laboratories Inc.
    Inventors: Jack A. DeJovin, Isabelle Jean DeJovin
  • Publication number: 20140287988
    Abstract: Provided herein are compositions, which include an active pharmaceutical ingredient and macrogol 15 hydroxystearate, and methods for using the same for treating diseases or disorder.
    Type: Application
    Filed: December 9, 2013
    Publication date: September 25, 2014
    Applicant: ALLERGAN, INC.
    Inventors: ANURADHA V. GORE, KEVIN S. WARNER, CHETAN P. PUJARA, RICHARD S. GRAHAM, AJAY P. PARASHAR, MU-LAN LEE, ROBERT S. JORDAN, SUKHON LIKITLERSUANG
  • Publication number: 20140276484
    Abstract: Clay composite sheets, mats, films or membranes without polymers. Methods of preparing clay composite sheets, mats, films or membranes without using polymers in the method. Methods of using clay composite sheets, mats, films or membranes prepared without using polymers. Antimicrobial dressing having organo-modified clay product. Transdermal delivery of drugs using organo-modified clay product and methods.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicant: Materials Modification Inc
    Inventors: Kausik Mukhopadhyay, Krishnaswamy Kasthuri Rangan, Tirumalai Srinivas Sudarshan
  • Publication number: 20140271770
    Abstract: Effective implantable medical devices for reducing and treating post-operative pain are provided. The implantable medical device comprises clonidine in an amount from about 1 wt. % to about 30 wt. % of the implantable medical device. At least one biodegradable polymer and a pore forming agent in an amount from about 1 wt. % to about 30 wt. % of the implantable medical device is also provided. The implantable medical device is configured to release the clonidine over a period of at least 48 hours. Methods of use are also disclosed.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 18, 2014
    Applicant: Warsaw Orthopedic, Inc.
    Inventors: Danielle L. Clay, William F. McKay
  • Publication number: 20140249163
    Abstract: The present disclosure describes new inhibitors or antagonists of Ras useful for the treatment of conditions resulting from Ras-induced or mediated cellular processes, including cellular proliferation, differentiation, apoptosis, senescence, and survival. These cellular processes may be associated with a non-malignant or malignant disease, disorder, or pathological condition. The present disclosure also describes a method for inhibiting such Ras-induced or mediated cellular processes. The method entails administering a Ras antagonist in an amount effective to inhibit such cellular processes.
    Type: Application
    Filed: October 5, 2012
    Publication date: September 4, 2014
    Applicant: PICES THERAPEUTICS LLC
    Inventors: James H. Wikel, Michael J. Brownstein
  • Patent number: 8815929
    Abstract: The present invention is directed to the treatment of skin erythema as exhibited in rosacea and other conditions characterized by increased erythema (redness) of the skin. These conditions exhibit dilation of blood vessels due to a cutaneous vascular hyper-reactivity. In particular, the present invention is directed to a novel composition and method for the treatment of skin erythema using ?1-adrenergic receptor (?1-adrenoceptor) agonists incorporated into cosmetic, pharmacological or dermatological compositions for topical application to the skin.
    Type: Grant
    Filed: October 11, 2010
    Date of Patent: August 26, 2014
    Assignee: Allergan, Inc.
    Inventors: Stuart D. Shanler, Andrew Ondo
  • Publication number: 20140235597
    Abstract: Solutions for perioperative intraocular application by continuous irrigation during ophthalmologic procedures are provided. These solutions include multiple agents that act to inhibit inflammation, inhibit pain, effect mydriasis (dilation of the pupil), and/or decrease intraocular pressure, wherein the multiple agents are selected to target multiple molecular targets to achieve multiple differing physiologic functions, and are included in dilute concentrations in a balanced salt solution carrier.
    Type: Application
    Filed: February 21, 2014
    Publication date: August 21, 2014
    Applicant: Omeros Corporation
    Inventors: Gregory A. Demopulos, Pamela Pierce Palmer, Jeffrey M. Herz